Purius Limited

Product: 
Life Sciences
Status: 
Closed
Sector: 
Pharmaceuticals
Aim of funding: 
Seed
HMRC Advance Assurance received: 
Yes

Purius Limited

Description: 

The Company was established in 2016 to exploit opportunities within the pharmaceutical sector, specifically delivering a solution to reduce manufacturing costs and increase output. To do so, the Company has established a novel technological process called ‘zero step purification’. The purification stage of pharmaceutical drug production is currently resource-inefficient. Current industry processes involve the use of resin, filters and other consumables, the use of which are no longer required when using the Purius component. The Company estimates that its platform can eliminate up to 60% of downstream processing costs (‘DSP’).

The Company’s process has a patent application in progress. The technology is fully scalable and enables higher throughput as well as efficient product purification for both the pharmaceutical and biotechnology industries.

Purius offers a near ‘single-vessel’ operation thereby vastly reducing GMP (Good Manufacturing Practices) complexity whilst releasing further scalability. In context, this means that biopharma companies can move from R&D to manufacturing to field deployment in one process, an opportunity which is not currently available.

Opportunity: 

The opportunity in biopharmaceuticals is significant and growing rapidly. Today, biopharmaceuticals generate global revenues of US$163 billion, making up about 20% of the pharma market.

The Company has identified through extensive market research that DSP is now the bottleneck costing an average 55%-80% of COG(cost of goods), greater than US$14bn p.a.

Emerging markets such ‘biosimilars’ (a biopharmaceutical drug designed to have active properties similar to one that has previously been licensed) are growing fast but under enormous cost pressure due to the significant costs associated with the current drug refinement processes.

At present, the purification arena is currently monopolised by a single manufacturer, GE Healthcare. The Company is keen to disrupt the market with its novel approach that offers significant cost savings and productivity improvements.

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.